TNF and Alzheimer disease: Interestingly, recent results about a randomized, placebo-controlled, double-blind, phase 2 trial using subcutaneous etanercept (a TNF-α inhibitor) treatment in patients with mild to moderate AD and follow-up during 24 months were published [58].